PMID- 34260534
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 28
DP  - 2021 Jul 16
TI  - Meta-analyzing the factors affecting the efficacy of gliflozins in patients with 
      heart failure based on heart failure trials.
PG  - e26561
LID - 10.1097/MD.0000000000026561 [doi]
LID - e26561
AB  - BACKGROUND: The factors affecting the efficacy of gliflozins in patients with 
      heart failure (HF) are not clear. We aimed to evaluate the effects of 11 
      important factors on the efficacy of gliflozins in HF patients. METHODS: 
      Randomized trials assessing gliflozins in HF patients were included. The outcome 
      of interest was composite HF outcome, a composite of cardiovascular death, or 
      hospitalization for HF. Meta-analysis was done according to 11 factors: status of 
      type 2 diabetes, sex, use of angiotensin receptor-neprilysin inhibitor, age, 
      history of hospitalization for HF, estimated glomerular filtration rate, body 
      mass index, New York Heart Association (NYHA) class, race, region, and left 
      ventricular ejection fraction. RESULTS: Compared with placebo, gliflozins reduced 
      the risk of composite HF outcome by 14% in the subgroup of patients with NYHA 
      class III or IV (hazard ratios [HR] 0.86, 95% confidence intervals [CI] 
      0.75-0.99), by 34% in the subgroup of patients with NYHA class II (HR 0.66, 95% 
      CI 0.59-0.74), and by 85% in the subgroup of patients with NYHA class I (HR 0.15, 
      95% CI 0.03-0.73). This between-group difference was approximate to statistical 
      significance (Psubgroup = .06). The benefit of gliflozins in HF patients was not 
      affected by the other 10 factors (Psubgroup >/= .123). CONCLUSIONS: Gliflozins are 
      applicable for a broad population of HF patients as for preventing HF events, 
      while gliflozins may lead to greater benefits in patients with mild HF than in 
      those with moderate to severe HF.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Yin, Daogen
AU  - Yin D
AD  - Department of General Medicine, Shenzhen Longhua District Central Hospital, 
      Shenzhen, China.
FAU - Qiu, Mei
AU  - Qiu M
AD  - Department of General Medicine, Shenzhen Longhua District Central Hospital, 
      Shenzhen, China.
FAU - Wei, Xubin
AU  - Wei X
AUID- ORCID: 0000-0003-2220-7101
AD  - Department of Cardiology, The Second Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
FAU - Duan, Xueyan
AU  - Duan X
AD  - Department of General Medicine, Shenzhen Longhua District Central Hospital, 
      Shenzhen, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Age Factors
MH  - Body Mass Index
MH  - Diabetes Mellitus, Type 2/epidemiology
MH  - Glomerular Filtration Rate
MH  - Heart Failure/*drug therapy/epidemiology
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Racial Groups
MH  - Randomized Controlled Trials as Topic
MH  - Sex Factors
MH  - Sodium-Glucose Transporter 2 Inhibitors/administration & dosage/*therapeutic use
MH  - Stroke Volume
PMC - PMC8284750
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2021/07/15 06:00
MHDA- 2021/07/29 06:00
PMCR- 2021/07/16
CRDT- 2021/07/14 17:28
PHST- 2020/12/05 00:00 [received]
PHST- 2021/06/12 00:00 [accepted]
PHST- 2021/07/14 17:28 [entrez]
PHST- 2021/07/15 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2021/07/16 00:00 [pmc-release]
AID - 00005792-202107160-00017 [pii]
AID - MD-D-20-12138 [pii]
AID - 10.1097/MD.0000000000026561 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Jul 16;100(28):e26561. doi: 
      10.1097/MD.0000000000026561.